Reevaluating Medication: De-prescribing Holds No Added Risks for Frail Elderly

An analysis suggests that de-prescribing preventive medications among frail, elderly adults does not heighten risks of death, hospitalization, or adverse heart events. The study underscores the necessity for further research, given the low certainty of evidence. Despite polypharmacy risks, findings indicate de-prescribing isn't linked to major health detriments.

A comprehensive analysis of previous studies reveals that de-prescribing preventive medications in frail, elderly adults does not increase the risk of death, hospitalization, or significant heart-related incidents.

The research, published in the journal BioMed Central (BMC) Geriatrics, indicates that de-prescribing does not elevate the risks of falls—a leading cause of disability among seniors—or fractures, nor does it diminish quality of life. Despite the findings, researchers from the Indian Council of Medical Research and Sweden's Karolinska Institutet caution that evidence certainty remains low, necessitating additional studies.

The analysis encompassed 15 studies with over 33,000 participants, examining the impact of de-prescribing preventive medications like antihypertensives, statins, and antidiabetics versus continuing with these treatments in older adults with advanced frailty or limited life expectancy. Results conclude that de-prescribing did not correlate with increased risks for all-cause mortality, hospitalizations, or major cardiac events, although certainty levels were assessed as very low.

(With inputs from agencies.)